SCHEMBL6000325

SCHEMBL6000325

CCC(N)(c1ccncc1)c1ccc(F)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
USP2 O75604 1/20 0.37
RAB9A P51151 1/20 0.37
KLKB1 P03952 2/20 0.34
DPP4 P27487 1/20 0.34
KCNN4 O15554 1/20 0.34
CYP19A1 P11511 1/20 0.33
NAMPT P43490 1/20 0.33
KIF11 P52732 3/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C8 P10632 1/20 0.32
TGFBR1 P36897 1/20 0.32
MAPK13 O15264 1/20 0.32
MAPK12 P53778 1/20 0.32
MAPK11 Q15759 1/20 0.32
MAPK14 Q16539 1/20 0.32
ALOX5 P09917 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5998633 0.83 CYP19A1 (0.42) RAB9AKCNN4CYP19A1KIF11CYP3A4
SCHEMBL5999951 0.82 USP2 (0.55) CYP17A1USP2RAB9ACYP19A1KIF11
SCHEMBL5999958 0.79 RAB9A (0.39) CYP17A1CYP11B1USP2RAB9AKIF11
SCHEMBL5999463 0.79 USP2 (0.39) CYP17A1CYP11B1CYP11B2USP2RAB9A
SCHEMBL5999689 0.79 CYP19A1 (0.55) CYP19A1
SCHEMBL6000236 0.79 KCNN4 (0.40) CYP17A1CYP11B1CYP11B2USP2RAB9A
SCHEMBL5999948 0.77 TSHR (0.38) USP2RAB9ACYP19A1KIF11CYP3A4
SCHEMBL5999593 0.77 TSHR (0.41) RAB9ACYP19A1KIF11CYP1A2CYP3A4
SCHEMBL5999962 0.76 CYP19A1 (0.39) CYP19A1KIF11CYP1A2CYP3A4
SCHEMBL6000276 0.75 CYP19A1 (0.43) CYP19A1KIF11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke K AND K BIOSCIENCE, INC. (US) 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060058357-A1 Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke SIGMAR1, GRM1, GRIN2C CYP17A1 4384/4885CYP11B1 2146/4885CYP11B2 1629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.